Basis of study
Visual fields, optical coherence tomography (OCT), and retinal metabolic analysis were performed at baseline and at 1 and 3 months after randomization. Researchers monitored for changes in visual fields, OCT, and retinal metabolic analysis over time. The initial demographic characteristics of the two groups were similar.
There were no significant differences in visual field or OCT indices in either group (all P > 5%). However, there was a significant decrease in optic nerve-adjusted mitochondrial flavoprotein fluorescence and average curve width from baseline to 1 month in those treated with Glauco-Health (β = –39, P = 0.003; β = –0.25, P = 0.01, respectively) but not in patients who were treated with placebo (P = 0.47 and 0.23).
“Mitochondrial dysfunction and death are increasingly implicated in retinal ganglion cell death in glaucoma and neuronal death in other neurodegenerative disorders,” Dr. Ritch explained. “Mitochondria become dysfunctional and die prior to neuronal cell death. Formulations with IOP-dependent neuroprotective effects could be additive in slowing progression rates by reversing mitochondrial dysfunction.”
Research such as that from this study could shift the treatment paradigm to stabilize mitochondria at an earlier disease stage, and prevent or retard neuronal cell death.
The findings “serve as a proof-of-concept for future trials testing the neuroprotective effect of supplement combinations in glaucoma,” according to the study.